Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROL vs ISORDIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
NITROL (nitroglycerin) is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase and increases cyclic guanosine monophosphate (c GMP) levels, leading to vasodilation.
Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.
Treatment of acute angina pectoris,Prophylaxis of angina pectoris (pre-exertional use),Management of acute myocardial infarction (FDA-approved),Congestive heart failure (off-label, in acute settings)
Angina pectoris (prophylaxis and acute treatment),Heart failure (off-label: adjunctive treatment in acute myocardial infarction)
Sublingual: 0.3-0.6 mg every 5 minutes as needed for angina, up to 3 doses in 15 minutes. Translingual spray: 1-2 sprays (0.4 mg/spray) under tongue every 5 minutes as needed, max 3 doses in 15 minutes. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours. Intravenous: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes until response, usual range 10-200 mcg/min.
Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.
1-4 minutes for nitroglycerin; clinical effect disappears within 30-60 minutes due to rapid metabolism and redistribution.
Terminal half-life: 1–4 hours (isosorbide dinitrate); clinical context: short duration requires frequent dosing or sustained-release formulations.
Primarily metabolized by nitrate reductase in the liver; also undergoes denitration by glutathione-dependent organic nitrate reductase and by hemoglobin in red blood cells.
Primarily hepatic via glutathione-organic nitrate reductase; also undergoes denitration to active metabolites (isosorbide-2-mononitrate and isosorbide-5-mononitrate).
Renal: minimal, <1% unchanged; extensive metabolism by liver, metabolites excreted renally. Biliary/fecal: negligible.
Renal: 80% as inactive metabolites; biliary/fecal: 20% as conjugates.
Approximately 60% bound to albumin.
~28% bound to albumin.
3.3 L/kg, indicating extensive distribution into tissues.
2–4 L/kg, indicating extensive tissue distribution.
Sublingual: ~40-60% (first-pass metabolism); Oral: <10% due to high first-pass; Transdermal: ~20-30% with continuous delivery; Intravenous: 100%.
Sublingual: ~40–60% (first-pass bypassed); oral: <30% due to extensive first-pass hepatic metabolism.
No specific adjustment for GFR; monitor for hypotension and methemoglobinemia in severe impairment. Use with caution in dialysis patients.
No specific GFR-based dose adjustments are recommended; however, caution is advised in severe renal impairment due to potential accumulation of metabolites.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% and titrate carefully. Child-Pugh C: Avoid use or use with extreme caution, consider alternative therapy.
In Child-Pugh class A: no adjustment. Child-Pugh class B and C: reduce dose by 50% and monitor for hypotension.
Sublingual/translingual: 5 mcg/kg/dose every 5-10 minutes as needed for acute angina, max 4 doses. IV: Start 0.25-0.5 mcg/kg/min, titrate by 0.5-1 mcg/kg/min, max 5 mcg/kg/min. Not recommended for neonates due to risk of methemoglobinemia.
Isosorbide dinitrate: not recommended for use in children due to lack of safety and efficacy data; no established pediatric dosing guidelines.
Start at low end of adult dose (sublingual 0.3 mg, transdermal 0.2 mg/hr, IV 5 mcg/min). Titrate slowly due to increased sensitivity and risk of hypotension. Monitor for orthostatic hypotension.
Elderly patients may have increased sensitivity to hypotension. Initiate with lowest doses (e.g., 5 mg orally twice daily) and titrate slowly. Monitor blood pressure and orthostatic changes.
Contraindicated in patients with erectile dysfunction who are using phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Do not use in patients with erectile dysfunction medications (PDE-5 inhibitors) due to risk of severe hypotension.
Risk of severe hypotension and syncope, especially in volume-depleted patients or those with low systolic blood pressure; tolerance and cross-tolerance with other nitrates may develop; abrupt cessation may precipitate angina; caution in patients with hypertrophic obstructive cardiomyopathy.
Hypotension (especially with volume depletion or alcohol),Tolerance with prolonged use (intermittent dosing recommended),Exacerbation of angina upon abrupt withdrawal,Use cautiously in hypertrophic cardiomyopathy
Hypersensitivity to nitroglycerin or any component; severe anemia; increased intracranial pressure (e.g., head trauma, cerebral hemorrhage); concurrent use with PDE-5 inhibitors; right ventricular infarction; constrictive pericarditis; cardiac tamponade.
Hypersensitivity to nitrates,Concurrent use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil),Severe anemia,Increased intracranial pressure (head trauma, cerebral hemorrhage),Acute circulatory failure (shock, vascular collapse)
Alcohol can exacerbate hypotensive effects and should be avoided. No specific food restrictions; however, high-fat meals may delay sublingual absorption but not clinically significant.
Avoid excessive alcohol consumption. No specific food interactions; however, high-fat meals may delay absorption of oral formulations. Maintain consistent dietary habits to minimize variations in drug effects.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, nitroglycerin has been shown to be embryotoxic in rats and rabbits at doses 20 times the human dose. Use in first trimester only if clearly needed. During second and third trimesters, may be used for management of preterm labor or pregnancy-induced hypertension, but monitor for maternal hypotension and fetal bradycardia.
Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. It should be used during pregnancy only if clearly needed. Potential fetal risks include hypotension and reduced uteroplacental perfusion, particularly in the first trimester. Second and third trimester risks are theoretical due to maternal hemodynamic changes. Avoid use near term due to risk of neonatal methemoglobinemia. FDA pregnancy category C.
Not known if nitroglycerin is excreted in human milk. M/P ratio not available. Because of potential for serious adverse reactions in nursing infants, discontinue nursing or discontinue drug, taking into account importance of drug to mother. Use with caution if breastfeeding; avoid high doses or continuous exposure.
Excretion in human milk is unknown. Due to potential for serious adverse reactions in nursing infants (e.g., methemoglobinemia), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio not reported.
No specific dose adjustments recommended for pregnancy-related PK changes. However, increased plasma volume and cardiac output in pregnancy may require higher doses for therapeutic effect. Start at lowest effective dose and titrate based on clinical response and blood pressure. For intravenous use in pregnancy, standard non-pregnant doses may be used but with careful titration.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance; however, no specific dose adjustments are established. Use lowest effective dose with careful titration to avoid hypotension. Initiate with 5-10 mg sublingual for acute episodes; for prophylaxis, 10-40 mg orally every 6 hours. Monitor for excessive hypotension.
Nitrol (nitroglycerin) is a potent vasodilator used primarily for angina pectoris. Sublingual tablets should be administered at first sign of attack; patient should be sitting to prevent syncope from hypotension. If pain persists after 3 doses 5 minutes apart, seek emergency care. Tolerance develops with sustained use; avoid long-acting formulations for acute episodes. Monitor for orthostatic hypotension and headache, common side effects. Contraindicated with concurrent use of PDE-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension.
Isordil (isosorbide dinitrate) is a nitrate vasodilator used for angina prophylaxis. Sublingual formulation provides rapid onset for acute attacks; oral sustained-release is for chronic prophylaxis. Tolerance develops with continuous exposure; use a daily nitrate-free interval of 10-12 hours. Avoid use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) due to severe hypotension. Monitor for headache, hypotension, and reflex tachycardia.
Take sublingual nitroglycerin at the first sign of chest pain; do not swallow. Place tablet under tongue and allow to dissolve.,Sit down before taking to avoid fainting due to drop in blood pressure.,If pain is not relieved after 1 dose, take a second dose after 5 minutes. If not relieved after 3 doses, call 911 immediately.,Store tablets in original glass container, tightly closed, away from light and heat. Replace every 6 months as potency decreases.,Avoid alcohol and erectile dysfunction drugs (e.g., Viagra, Cialis) as they can cause severe hypotension.,Common side effects include headache, dizziness, and flushing. Headache may indicate effectiveness.
Take sublingual isordil at the first sign of an angina attack; sit down before using to avoid dizziness.,For chronic prophylaxis, take as prescribed; do not skip doses to maintain the nitrate-free interval.,Avoid alcohol as it can increase the risk of hypotension and dizziness.,Report any severe headaches, worsening chest pain, or fainting to your healthcare provider immediately.,Never take erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on isordil.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROL vs ISORDIL, answered by our medical review team.
NITROL is a Nitrate Vasodilator that works by NITROL (nitroglycerin) is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase and increases cyclic guanosine monophosphate (c GMP) levels, leading to vasodilation.. ISORDIL is a Nitrate Vasodilator that works by Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROL and ISORDIL depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROL is: Sublingual: 0.3-0.6 mg every 5 minutes as needed for angina, up to 3 doses in 15 minutes. Translingual spray: 1-2 sprays (0.4 mg/spray) under tongue every 5 minutes as needed, max 3 doses in 15 minutes. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours. Intravenous: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes until response, usual range 10-200 mcg/min.. The standard adult dose of ISORDIL is: Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROL and ISORDIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROL is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, nitroglycerin has been shown to be embryotoxic in rats and rabbits at doses 20 times the human d. ISORDIL is classified as Category C. Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.